Article Information
History
- August 9, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Kara M. Calhoun1,
- Emily Armantrout2,
- Katie Poch2,*,
- Silvia Caceres2,
- Valerie K. Lovell2,
- Marion Jones2,
- Kenneth C. Malcolm2,
- Brian Vestal3,
- Emily Wheeler2,
- Noel Rysavy2,
- Jordan Manzer4,
- Ibrahim Aboellail4,
- Delphi Chatterjee4 and
- Jerry A. Nick1,2
- 1Department of Pulmonary Sciences and Critical Care Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA
- 2Department of Medicine, National Jewish Health, Denver, CO, 80206, USA
- 3Center for Genes, Environment, and Health, National Jewish Health, Denver, CO, USA
- 4Mycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, 1682 Campus Delivery, Fort Collins, CO, USA
- ↵*Corresponding Author
E-mail: pochk{at}njhealth.org (KP)
Posted August 09, 2024.
Prospective Analysis of urINe LAM to Eliminate NTM Sputum Screening (PAINLESS) study: Rationale and trial design for testing urine lipoarabinomannan as a marker of NTM lung infection in cystic fibrosis
